BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34708436)

  • 1. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
    Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
    J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
    Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
    J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.
    Cheng F; Li Q; Wang J; Zeng F; Zhang Y
    J Clin Pharm Ther; 2021 Dec; 46(6):1636-1649. PubMed ID: 34342024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Wuzhi Capsules on Blood Concentration of Tacrolimus in Renal Transplant Recipients.
    Yan L; Yang ZQ; Shi YY; Ren J; Yang CL; Wan ZL; Bai YJ; Luo LM; Wang LL; Li Y
    Ann Transplant; 2019 Nov; 24():594-604. PubMed ID: 31712547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
    Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
    Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
    Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Wuzhi preparations on tacrolimus in CYP3A5 expressers during the early period after transplantation: A real-life experience from heart transplant recipients.
    Zhou Y; Huang X; Liu L; Zeng F; Han Y; Zhang J; Zhou H; Zhang Y
    Transpl Immunol; 2023 Feb; 76():101748. PubMed ID: 36423734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
    Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
    Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E; Şahin G; Kaltuş Z; Çolak E
    Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
    Buendia JA; Bramuglia G; Staatz CE
    Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interactions between tacrolimus and Wuzhi capsule in liver transplant recipients: Genetic polymorphisms affect the drug interaction.
    Huang S; Song W; Jiang S; Li Y; Wang M; Yang N; Zhu H
    Chem Biol Interact; 2024 Mar; 391():110906. PubMed ID: 38340974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
    Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of WuZhi preparations on tacrolimus in pediatric and adult patients carrying the CYP3A5*1 allele of heart transplant during the early period after transplantation.
    Liu L; Zhou Y; Huang X; Chen H; Gong Z; Zhang J; Zeng F; Zhou H; Zhang Y
    Clin Transplant; 2024 Jan; 38(1):e15237. PubMed ID: 38289887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Donor and Recipient
    Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
    Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose.
    Berger FA; Mulder MB; Ten Bosch-Dijksman W; van Schaik RHN; Coenen S; de Winter BCM
    Br J Clin Pharmacol; 2019 Aug; 85(8):1852-1854. PubMed ID: 31190414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients.
    Jannot AS; Vuillemin X; Etienne I; Buchler M; Hurault de Ligny B; Choukroun G; Colosio C; Thierry A; Vigneau C; Moulin B; Rerolle JP; Heng AE; Subra JF; Legendre C; Beaune P; Loriot MA; Thervet E; Pallet N
    Ther Drug Monit; 2016 Apr; 38(2):223-9. PubMed ID: 26829596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation.
    Wu Y; Fang F; Wang Z; Wen P; Fan J
    Eur J Clin Pharmacol; 2021 Jun; 77(6):859-867. PubMed ID: 33386894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.